About Azanta
Azanta is a company based in Copenhagen (Denmark) founded in 1994 by Claus Juan Moller San Pedro was acquired by Norgine in March 2020. Azanta has raised $15.82 million across 2 funding rounds from investors including Norgine, European Equity Partners and Norgine Ventures. The company has 3 employees as of December 31, 2018. Azanta operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
- Headquarter Copenhagen, Denmark
- Employees 3 as on 31 Dec, 2018
- Founders Claus Juan Moller San Pedro
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Azanta A/S
-
Annual Revenue
$6.92 K (USD)27as on Dec 31, 2018
-
Net Profit
$882.79 K (USD)0as on Dec 31, 2017
-
EBITDA
Not available
-
Total Equity Funding
$15.82 M (USD)
in 2 rounds
-
Latest Funding Round
$6.98 M (USD), Series B
Oct 01, 2015
-
Investors
Norgine
& 2 more
-
Employee Count
3
as on Dec 31, 2018
-
Acquired by
Norgine
(Mar 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Azanta
Azanta has successfully raised a total of $15.82M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.98 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Azanta
Azanta has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Norgine, European Equity Partners and Norgine Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in life sciences companies is facilitated by EEP.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
Locked | Locked | Locked |
Investor details for Azanta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Azanta
Investment portfolio details for Azanta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Azanta
Detailed financials for Azanta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Azanta Comparisons
Peer comparison for Azanta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Azanta
Azanta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
Detailed competitors of Azanta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Azanta
Complete news archive for Azanta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Azanta
Azanta was founded in 1994 and raised its 1st funding round 20 years after it was founded.
Azanta is headquartered in Copenhagen, Denmark.
Claus Juan Moller San Pedro is the current CEO of Azanta. They have also founded this company.
Azanta is a funded company, having raised a total of $15.82M across 2 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Azanta is 3.
Annual revenue of Azanta is $6.92K as on Dec 31, 2018.
Azanta was founded in 1994 in Copenhagen, Denmark, focusing on the pharmaceutical and medical device sectors. Treatments for orphan oncology indications are developed, alongside devices for womens health monitoring. Lead candidates include Nimoral and Angusta. A range of specialty pharmaceutical products is marketed and distributed via third-party agreements. Operations center on intrauterine devices for contraception, such as the CE-approved Silverline Cu 380 and Flexi-T.
Azanta's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
Azanta has 3 investors. Key investors include Norgine, European Equity Partners, and Norgine Ventures.